US 11,718,669 B2
Anti-TIGIT and anti-CD96 antibodies
Dhan Sidhartha Chand, Lexington, MA (US); Zahra Jawad, Lexington, MA (US); Olga Ignatovich, Lexington, MA (US); Nicola Anne Ramsay, Lexington, MA (US); Spencer Campbell, Lexington, MA (US); Beth Wensley, Lexington, MA (US); Emmanuel Cyrille Pascal Briend, Lexington, MA (US); K. Mark Bushell, Lexington, MA (US); Benjamin Maxime Morin, Lexington, MA (US); and Veronica Franciszka Ilkow, Lexington, MA (US)
Assigned to AGENUS INC., Lexington, MA (US)
Filed by AGENUS INC., Lexington, MA (US)
Filed on Aug. 10, 2022, as Appl. No. 17/818,840.
Application 17/818,840 is a continuation of application No. 17/662,036, filed on May 4, 2022, abandoned.
Claims priority of provisional application 63/201,537, filed on May 4, 2021.
Prior Publication US 2023/0014036 A1, Jan. 19, 2023
Int. Cl. C07K 16/30 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 37 Claims
OG exemplary drawing
 
1. A multispecific molecule comprising:
(a) a first antigen-binding region that specifically binds to human CD96, the first antigen-binding region comprising a first heavy chain variable region (VH) comprising CDRs CDRH1, CDRH2, and CDRH3, and a first light chain variable region (VL) comprising CDRs CDRL1, CDRL2, and CDRL3; wherein the first VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence of SEQ ID NO: 38; and the first VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence of SEQ ID NO: 39; and
(b) a second antigen-binding region that specifically binds to human TIGIT, the second antigen-binding region comprising a second VH comprising CDRs CDRH1, CDRH2, and CDRH3, and a second VL comprising CDRs CDRL I, CDRL2, and CDRL3; wherein the second VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence of SEQ ID NO: 40; and/or the second VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence of SEQ ID NO: 41.